#	Pagina
attuale pagina	/open-fp7/projects/109903/index.html

VASCAMY

Vascular and Aymloid Predictors of Neurodegeneration and Cognitive Decline in Nondemented Subjects

Coordinatore	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN Organization address address: GESCHWISTER SCHOLL PLATZ 1 city: MUENCHEN postcode: 80539 contact info Titolo: Ms. Nome: Dorothee Cognome: Hasebrink Email: send email Telefono: +49 89 2180 3605 Fax: +49 89 2180 2985
Nazionalità Coordinatore	Germany [DE]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-CIG
Funding Scheme	MC-CIG
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-09-01 - 2017-08-31

Partecipanti

#	participant	country	role	EC contrib. [€]
1	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN Organization address address: GESCHWISTER SCHOLL PLATZ 1 city: MUENCHEN postcode: 80539 contact info Titolo: Ms. Nome: Dorothee Cognome: Hasebrink Email: send email Telefono: +49 89 2180 3605 Fax: +49 89 2180 2985	DE (MUENCHEN)	coordinator	100˙000.00

Mappa

Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

disease networks dti age years florbetaben amyloid network memory stage decline brain executive predict occurs mri cerebrovascular persons dementia function cognitive clinical szlig ad vascular degeneration subjects pathology pet white episodic

Obiettivo del progetto (Objective)

'Alzheimer’s disease (AD) is the most frequent cause of dementia that affects one in 14 persons over the age 65 years and one in six persons over the age of 80 years. Increased deposition of the protein beta-amyloid (Aß) is a core brain pathology of AD that occurs years before the onset of clinical symptoms of dementia. Together with Aß, cerebrovascular disease, visible as on a MR image as white matter abnormalities, frequently co-occurs. A major question is whether Aß and cerebrovascular disease independently from each other predict disease progression and cognitive decline. The overall goal of the combined amyloid PET and MRI study is to assess how Aß pathology and vascular white matter damage contribute to cognitive decline through particular neuronal networks at an early stage of the disease. To this end, we will assess in a prospective 4-year longitudinal neuroimaging study 80 subjects with mild cognitive impairment (MCI) of episodic memory or executive function and 50 elderly cognitively healthy subjects (HC). Brain changes in association with Aß (florbetaben PET) and white matter degeneration (MRI, DTI) will be assessed in two major networks 1) temporo-parietal network that is typically associated with episodic memory, and 2) a subcortical-prefrontal network that is typically associated with executive function. Specifically, florbetaben PET binding and volumes of WMH and lacunes at baseline will be tested as predictors of fiber tract degeneration (DTI) and grey matter atrophy of those networks and cognitive decline during annual follow-up assessments. We expect that the results of this study will provide us with a clear understanding of the joint effects of the Aß and vascular white matter pathology on brain degeneration to predict cognitive decline during an early disease stage. This will help to identify subjects at risk of developing eventually dementia and will provide endpoints for clinical trials of disease modifying drugs to prevent dementia.'